ENVB • NASDAQ
Enveric Biosciences, Inc.
$7.24
Stock Details
| Market Cap | 1,491,237 |
|---|---|
| Day Change | 1.54 (27.02%) |
| Volume | 302,539 |
| Avg Volume | 66,497 |
| Price Range | 5.52-1444.5 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Financial Overview
| 52 Week High | 96.36 |
|---|---|
| 52 Week High Date | 2025-01-07 |
| 52 Week Low | 5.52 |
| 52 Week Low Date | 2025-11-04 |
| 10D Avg Trading Vol | 0.18861 |
| YTD Price Return Daily | -91.171 |
| MTD Price Return Daily |
Cash Flow
| TTM/Share | -10.57672 |
|---|---|
| Annual/Share | -11.3955 |
| Quarterly/Share | -2.1539 |
Price-to-Earnings
| Annual Ratio | 1.8356 |
|---|---|
| Quarterly Ratio | 2.4253 |
| TTM |
Revenue
| 3Y Growth | 3.35 |
|---|---|
| 5Y Growth | |
| Annual/Share | -11.87 |
| TTM/Share | 3992 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -19.14 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 1.7176 |
|---|---|
| Annual Ratio | 2.2884 |
| TTM | 1.3689 |